Clinical Trials
70 trialsTAURUS
European Myeloma Network B.V.
IsAMYP
Intergroupe Francophone du Myelome
SPODUMENE
Peking University People's Hospital
ATG-010(Selinexor) in Combination With Chemotherapy in RRMM
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation
Icahn School of Medicine at Mount Sinai
Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma
Singapore General Hospital
LENDER
Kosin University Gospel Hospital
Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma
Sun Yat-sen University
VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma
Sun Yat-sen University
Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) in the Treatment of Untreated Early Non-upper Respiratory Tract or Advanced Extranodal NK/T-cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM
Shanghai Changzheng Hospital
PVd Versus Vd in NDMM Patients With RI
RenJi Hospital
Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis
Barbara Ann Karmanos Cancer Institute
Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma
Poitiers University Hospital
FIL_KLIMT
Fondazione Italiana Linfomi - ETS
KMM1910
Samsung Medical Center
Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple Myeloma
PETHEMA Foundation
KMM2002
Samsung Medical Center
Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis
Peking Union Medical College Hospital
A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment
Hellenic Society of Hematology
A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor
Hellenic Society of Hematology
DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.
PETHEMA Foundation
LYTPET
British Columbia Cancer Agency
GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma
Beijing Tongren Hospital
Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma
Peking University
Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL
Samsung Medical Center
VIDL+ASCT
Samsung Medical Center
IFM2018-01
University Hospital, Toulouse
the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy
Henan Cancer Hospital
GPED Regimen for Relapsed/Refractory or Advanced ENKTCL
Beijing Tongren Hospital
Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma
Henan Cancer Hospital
PEG-ASP+Gemoxd vs. PEG-ASP+CHOP as First-line Chemotherapy to Treatment NK/T-cell Lymphoma With Early Stage
Hunan Cancer Hospital
OPTIMAL
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
DARIA
Hellenic Society of Hematology
MM-POM-2018
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado
Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM
Shanghai Zhongshan Hospital
Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma
National University Hospital, Singapore
Efficacy and Toxicity Study of Pomalidomide and Dexamethasone in Patients Who Have Relapsed After Exposure to Lenalidomide and Bortezomib
National University Hospital, Singapore
A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCL
Ruijin Hospital
GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell Lymphoma
Sichuan University
BOMB-THROW
Seoul National University Hospital
Tolerability and Efficacy of Modified VCD Regimens in Previously Untreated Multiple Myeloma.
Jinling Hospital, China
Modified MRCUKALLâ…«/ECOGE2993 Regimen for ALL
Sun Yat-sen University
METDEXA-MM
University of Campinas, Brazil
GAD-M Regimen As First-Line Treatment in Untreated Extranodal NK/T Cell Lymphoma
Sun Yat-sen University
Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy
Zhejiang University
Efficacy of Monosialotetrahexosylganglioside in the Prophylactic Treatment of Bortezomib-induced Peripheral Neuropathy
Sun Yat-sen University
Olanzapine Against Delayed Nausea and Vomiting in Women Receiving Carboplatin Plus Paclitaxel
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Oral Steroids for Regorafenib-induced Fatigue/Malaise in Unresectable mCRC (KSCC1402/HGCSG1402)
Clinical Research Support Center Kyush